UroGen Pharma Ltd (LTS:0XOD)

$ 11.31 -0.26 (-2.3%) Market Cap: 467.57 Mil Enterprise Value: 339.92 Mil PE Ratio: 0 PB Ratio: 18.20 GF Score: 73/100

Q3 2024 Urogen Pharma Ltd Earnings Call Transcript
Nov 06, 2024

$11.89 (+0.92%)

Earnings
Q2 2024 Urogen Pharma Ltd Earnings Call Transcript
Aug 13, 2024

$14.64 (+2.20%)

Earnings
Q1 2024 Urogen Pharma Ltd Earnings Call Transcript
May 13, 2024

$12.98 (+5.10%)

Earnings
Q4 2023 Urogen Pharma Ltd Earnings Call Transcript
Mar 14, 2024

$16.23 (-6.27%)

Earnings
Q3 2023 Urogen Pharma Ltd Earnings Call Transcript
Nov 14, 2023

$11.5 (-0.61%)

Earnings
Q2 2023 Urogen Pharma Ltd Earnings Call Transcript
Aug 10, 2023

$20.59 (-2.65%)

Earnings
Urogen Pharma Ltd to Host UGN-102 Data Event Transcript
Jul 27, 2023
Urogen Pharma Ltd at Goldman Sachs Healthcare Conference Transcript
Jun 14, 2023
Urogen Pharma Ltd at Jefferies Healthcare Conference Transcript
Jun 09, 2023
Q1 2023 Urogen Pharma Ltd Earnings Call Transcript
May 11, 2023

$12.12 (+1.76%)

Earnings
Urogen Pharma Ltd at H.C. Wainwright BioConnect Investor Conference Transcript
May 02, 2023
Q4 2022 Urogen Pharma Ltd Earnings Call Transcript
Mar 16, 2023

$10.15

Earnings
Q3 2022 Urogen Pharma Ltd Earnings Call Transcript
Nov 10, 2022

$11.71

Earnings
Urogen Pharma Ltd UGN-102 and Non-Muscle Invasive Bladder Cancers Briefing Transcript
Oct 18, 2022
Q2 2022 Urogen Pharma Ltd Earnings Call Transcript
Aug 11, 2022

$8.7

Earnings
Q1 2022 Urogen Pharma Ltd Earnings Call Transcript
May 10, 2022

$7.46

Earnings
Q4 2021 Urogen Pharma Ltd Earnings Call Transcript
Mar 21, 2022

$9.44 (+21.81%)

Earnings
Urogen Pharma Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2022
Q3 2021 Urogen Pharma Ltd Earnings Call Transcript
Nov 15, 2021

$16.82

Earnings
Urogen Pharma Ltd To Host the Spotlight Event Transcript
Nov 10, 2021
Q2 2021 Urogen Pharma Ltd Earnings Call Transcript
Aug 04, 2021

$15.41

Earnings
Urogen Pharma Ltd at Ladenburg Thalmann Virtual Healthcare Conference Transcript
Jul 14, 2021
Urogen Pharma Ltd at Goldman Sachs Global Healthcare Conference (Virtual) Transcript
Jun 09, 2021
Q1 2021 Urogen Pharma Ltd Earnings Call Transcript
May 13, 2021

$16.85 (-5.92%)

Earnings
Q4 2020 Urogen Pharma Ltd Earnings Call Transcript
Mar 18, 2021

$18.04

Earnings
Urogen Pharma Ltd at Cowen Healthcare Conference (Virtual) Transcript
Mar 02, 2021
Urogen Pharma Ltd at JPMorgan Healthcare Conference (Virtual) Transcript
Jan 13, 2021
Q3 2020 Urogen Pharma Ltd Earnings Call Transcript
Nov 09, 2020

$25.52 (-13.49%)

Earnings
Q2 2020 Urogen Pharma Ltd Earnings Call Transcript
Aug 10, 2020

$29.5

Earnings
Urogen Pharma Ltd Annual Shareholders Meeting Transcript
Jun 08, 2020
Q1 2020 Urogen Pharma Ltd Earnings Call Transcript
May 07, 2020

$29.5

Earnings
UroGen Pharma Ltd. - Special Call Transcript
Apr 16, 2020
Q4 2019 Urogen Pharma Ltd Earnings Call Transcript
Mar 02, 2020

$29.5

Earnings
Urogen Pharma Ltd at JPMorgan Healthcare Conference Transcript
Jan 15, 2020
Q3 2019 Urogen Pharma Ltd Earnings Call Transcript
Nov 12, 2019

$51.33

Earnings
Urogen Pharma Ltd Corporate Analyst Meeting Transcript
Sep 24, 2019
Q2 2019 Urogen Pharma Ltd Earnings Call Transcript
Aug 12, 2019

$51.33

Earnings
Urogen Pharma Ltd at Goldman Sachs Global Healthcare Conference Transcript
Jun 12, 2019
Q1 2019 Urogen Pharma Ltd Earnings Call Transcript
May 09, 2019

$51.33

Earnings
Q4 2018 Urogen Pharma Ltd Earnings Call Transcript
Feb 28, 2019

$51.33

Earnings

Urogen Pharma Ltd UGN-102 and Non-Muscle Invasive Bladder Cancers Briefing Transcript

Oct 18, 2022 / 01:00PM GMT

Release Date Price: $8.7

Transcript

Tara Sobierajski

Good morning, and welcome to the UroGen Pharma KOL webinar. (Operator Instructions) A question-and-answer session will follow the formal presentations. (Operator Instructions) As a reminder, this call is being recorded and a replay will be made available on the UroGen website following the conclusion of the event.

I'd now like to turn the call over to Vincent Perrone, Senior Director of Investor Relations. Please go ahead, Vincent.

Vincent I. Perrone

UroGen Pharma Ltd. - Senior Director of IR

Good morning, everyone. As Tara mentioned, my name is Vincent Perrone, Head of Investor Relations for UroGen Pharma. I'd like to welcome you to UroGen's key opinion leader webinar for investors and analysts. The topic for today's webinar will cover the unmet need and treatment landscape for non-muscle invasive bladder cancers, or NMIBC, with a focus on low-grade, intermediate-risk NMIBC.

Next slide. Before we begin, let me remind you that during today's call, the company will be making forward-looking statements concerning future events,

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.